Amgen Inc Stock (AMGN) Moved Down by 3.08% on Mar 5: Key Drivers Unveiled

Amgen's stock experienced a decline today, primarily influenced by a recent analyst downgrade and concerns surrounding the company's financial outlook and valuation. An investment firm downgraded Amgen to a "Hold" rating, citing a less favorable risk/reward profile following a period of strong stock performance and an expanded valuation. This adjustment reflects a more cautious stance on the company's near-term prospects.

The downgrade was partly driven by an analysis of Amgen's recent quarterly financial results, which indicated mixed performance. While sales of key products remained robust, the company faced margin erosion and a deceleration in overall growth. Furthermore, the financial guidance provided for 2026 suggests a notable slowdown in both revenue and non-GAAP earnings per share growth compared to the previous year. There are also indications that political pressures related to drug discounts are contributing to softness in profitability.

From a valuation perspective, the company's forward price-to-earnings ratio has reached a multi-year high, making the current stock levels less attractive for new investments. Although Amgen maintains a robust long-term pipeline with promising candidates, some late-stage clinical programs, such as the cardiovascular outcomes study for olpasiran, have experienced slower accrual, pushing back completion timelines. Additionally, the company anticipates increased biosimilar competition for key drugs like Prolia, Xgeva, and the entry of generics for Otezla in Europe, which are expected to create headwinds. The combination of these factors appears to have contributed to the negative market sentiment and the downward movement in the share price.

Technically, Amgen Inc (AMGN) shows a MACD (12,26,9) value of [10.04], indicating a neutral signal. The RSI at 58.34 suggests neutral condition and the Williams %R at -40.64 suggests oversold condition. Please monitor closely.

Amgen Inc (AMGN) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $36.75B, ranking 14 in the industry. The net profit is $7.71B, ranking 10 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $353.18, a high of $432.00, and a low of $200.00.

Company Specific Risks:

• Decelerating revenue and earnings per share growth projected for 2026, coupled with margin erosion observed in Q4 2025 financials.
• Significant top-line pressure anticipated from biosimilar competition and the loss of exclusivity for key drug franchises such as Prolia and Xgeva, which are projected to experience substantial sales declines in 2026.
• The stock's current elevated valuation, with its forward P/E ratio nearing multi-year highs, creates an unattractive risk/reward profile given the outlook for slowing growth.